376 related articles for article (PubMed ID: 25530379)
1. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
[TBL] [Abstract][Full Text] [Related]
2. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
3. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA; Xu J; Chen H; Kader AK
Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
[TBL] [Abstract][Full Text] [Related]
4. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
5. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
6. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?
Butoescu V; Ambroise J; Stainier A; Dekairelle AF; Gala JL; Tombal B
Prostate; 2014 Apr; 74(4):365-71. PubMed ID: 24265090
[TBL] [Abstract][Full Text] [Related]
7. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
8. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
9. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
11. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
12. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
13. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
14. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
15. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
16. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
17. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
18. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
[TBL] [Abstract][Full Text] [Related]
19. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
20. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
